文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

玻璃体腔注射雷珠单抗单药治疗后早产儿视网膜病变复发的时间与危险因素

Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

回顾性分析50例(每例取较重眼)因1型早产儿视网膜病变接受玻璃体腔注射雷珠单抗单药治疗的患儿,平均随访31周。32眼(64%)复发,平均复发时间7.9±2.7周,94%的复发发生于治疗后2.5至12.0周,复发风险率在8周达峰值。广泛视网膜新生血管(P=0.005)和注射后需氧疗(P=0.016)是复发的独立危险因素。

要点

  • 32/50眼(64%)在玻璃体腔注射雷珠单抗后平均7.9±2.7周复发,94%发生于2.5至12.0周。
  • 累及初始视网膜外纤维血管增殖部位的复发(4.5±1.4周)早于仅在新血管推进缘的复发(9.1±2.0周),P<0.001。
  • 广泛视网膜新生血管(P=0.005)和注射后需氧疗(P=0.016)是复发的独立危险因素。

核心结论

  • 1型早产儿视网膜病变在玻璃体腔注射雷珠单抗单药治疗后需长期随访警惕复发,尤其治疗后前12周以及存在广泛视网膜新生血管或长时间氧疗者。

研究设计与样本

  • 回顾性研究纳入50例(每例取病变较重眼)因1型早产儿视网膜病变接受玻璃体腔注射雷珠单抗单药治疗的患儿,平均随访31周。
  • 复发(视网膜外纤维血管增殖再出现)由RetCam广角眼底成像和双目间接检眼镜确定。
  • 采用Kaplan-Meier生存分析(以复发为终点)估计复发风险时间,用寿命表分析的风险函数确定时变复发风险率,用logistic回归分析探索复发危险因素。

主要发现

  • 50眼中32眼(64%)复发,平均复发时间7.9±2.7周。
  • 94%的复发发生于玻璃体腔注射雷珠单抗后2.5至12.0周,复发风险率在8周达最高。
  • 累及初始视网膜外纤维血管增殖部位的复发(4.5±1.4周)显著早于仅在新血管推进缘的复发(9.1±2.0周),P<0.001。
  • 复发的独立危险因素包括广泛视网膜新生血管(P=0.005)和玻璃体腔注射雷珠单抗后需氧疗(P=0.016)。

关键数值与推荐

  • 复发定义为视网膜外纤维血管增殖再出现,由RetCam广角眼底成像和双目间接检眼镜确定。
  • 复发独立危险因素:广泛视网膜新生血管P=0.005,注射后需氧疗P=0.016。

临床怎么用

  • 原文结论为:玻璃体腔注射雷珠单抗单药治疗后应长期随访警惕1型早产儿视网膜病变复发,尤其治疗后前12周以及存在广泛视网膜新生血管或长时间氧疗者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate timing and risk factors of recurrent retinopathy of prematurity (ROP) after intravitreal ranibizumab (IVR) monotherapy. METHODS: Fifty eyes (the more severe eye) of 50 infants treated with IVR monotherapy for type 1 ROP were studied retrospectively. The mean follow-up time was 31 weeks after IVR. Recurrent ROP (recurrence of extraretinal fibrovascular proliferation [EFP]) was determined by RetCam wide-angle fundus imaging and binocular indirect ophthalmoscopy. Risk time of recurrence was estimated by Kaplan-Meier survival analysis with recurrence as the endpoint. Time-varying recurrence hazard rate was determined using the hazard function of life-table analysis. The risk factors of recurrence were explored by logistic regression analysis. RESULTS: Recurrence of ROP occurred in 32 (64%) of 50 eyes at 7.9 ± 2.7 weeks after IVR. Most of recurrence (94%) occurred in 2.5 to 12.0 weeks following IVR treatment. The recurrence hazard rate reached its maximum at 8 weeks. Recurrence affecting the initial site of EFP occurred significantly earlier than recurrence only at the new vascular advancing edge (4.5 ± 1.4 weeks versus 9.1 ± 2.0 weeks after IVR, P < 0.001). The independent risk factors of recurrence included extensive retinal neovascularization (P = 0.005) and oxygen requirement after IVR (P = 0.016). CONCLUSIONS: Recurrence of type 1 ROP should be carefully watched in a long-term follow-up after IVR monotherapy, particularly in the first 12 weeks after IVR and for those with extensive retinal neovascularization or prolonged oxygen therapy.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Lyu J, Zhang Q, Chen CL, et al. Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors. Invest Ophthalmol Vis Sci. 2017. PMID: 28324112. doi:10.1167/iovs.16-20680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。